title: Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of docetaxel regimen as second-line after failure of a platinum-based chemotherapy.
  
  
  METHODS
  Between May 2005 and June 2008, we retrospectively analyzed the data of 22 patients who had evidence of disease progression after one prior platinum-based regimen for metastatic urothelial carcinoma. Patients were treated with two different docetaxel dose schedules: (1) docetaxel 60 mg/m(2) every 21 days for unfit patients or (2) docetaxel 75 mg/m(2) every 21 days for fit patients.
  
  
  RESULTS
  Median number of docetaxel cycles was three. Overall disease control rate was 18 %. Of the 22 patients, no patient achieved complete or partial response and four patients had stable disease. Median progression-free survival was 1.67 months and median overall survival was 3.12 months. Neutropenia was the most common adverse event.
  
  
  CONCLUSIONS
  This study identifies that docetaxel as second-line chemotherapy has low activity and was associated with significant toxicity.
authors.affiliation: GU, CNS and Sarcoma Program, Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Catalonia, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Morales-Barrera
authors.forename: C
authors.initials: C
authors.lastname: Suárez
authors.forename: C
authors.initials: C
authors.lastname: Valverde
authors.forename: I
authors.initials: I
authors.lastname: Nuñez
authors.forename: X
authors.initials: X
authors.lastname: Maldonado
authors.forename: J
authors.initials: J
authors.lastname: Morote
authors.forename: J
authors.initials: J
authors.lastname: Carles
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016879:Salvage Therapy; D043823:Taxoids / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel